Politics
Briefing: India's cheap weight-loss drugs could reshape global obesity fight
Strategic angle: With India’s semaglutide patent expiring on 20 March, about 50 branded generics are expected to enter the market.
editorial-staff
1 min read
Updated 25 days ago
India's semaglutide patent is scheduled to expire on March 20, allowing for the introduction of approximately 50 branded generics into the market.
This development could enhance the accessibility of weight-loss medications, potentially increasing treatment options for obesity on a global scale.
The influx of generics may also lead to competitive pricing, influencing market dynamics and healthcare strategies in various regions.